BREAST-CANCER AND CLINICAL UTILITY OF CA-15-3 AND CEA

被引：35

作者：

JAGER, W

KRAMER, S

PALAPELAS, V

NORBERT, L

机构：

[1] Department Obstetrics Gynecology, University of Erlangen-Nuremberg, Erlangen

来源：

SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION | 1995年 / 55卷

关键词：

CARCINOEMBRYONIC ANTIGEN; FOLLOW-UP; METASTASES; MUCIN; TUMOR MARKER;

D O I：

10.3109/00365519509090570

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

This manuscript summarizes the experiences with CA 15-3 and CEA obtained in 8 000 breast cancer patients. These markers were usually in normal range (CEA <6 mu g/L, CA 15-3 <40 U/L) before surgery and increased only before the development of distant metastases. 80% of all patients with metastases had elevated marker levels several months before or at the time of detection of metastases. Therefore CA 15-3 and CEA determinations should be used as an easy method for screening of metastases during follow-up of breast cancer patients.

引用

页码：87 / 92

页数：6

共 10 条

[1]

BONADONNA G, 1993, INT J CANCER, V555, P1

[2] IMPROVING THE QUALITY-OF-LIFE DURING CHEMOTHERAPY FOR ADVANCED BREAST-CANCER - A COMPARISON OF INTERMITTENT AND CONTINUOUS TREATMENT STRATEGIES [J].